



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

IMAtinib (Gleevec® 800 mg)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Second line treatment of Unresectable/Recurrent/Metastatic GIST.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000

Standard Protocol:

DRUG	DOSE	ADMINISTRATION
IMAtinib	800 mg PO once daily	To be given with a meal and a large glass of water.
To be given continuously until disease progression or intolerable toxicity.		

Special instructions: Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.

Treatment Description:

Cycle	Date	IMAtinib	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No